Tyme Technologies (TYME) Announces Board Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
TYME Technologies, Inc. Announces Changes to its Board of Directors
March 25, 2022 8:00 AM EDTIndustry veteran, Christine D. Baker, joins Board of Directors
Douglas A. Michels appointed Chairman of the Board
BEDMINSTER, N.J.--(BUSINESS WIRE)-- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced changes to its Board of Directors.
Christine D. Baker Named to Board of Directors
The Company is pleased to announce that Christine D. Baker has been appointed to TYMEs Board of Directors. Ms. Baker brings over 30 years of experience in the biotech/pharmaceutical industry, with expertise in... More
